# Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

> **NCT06101329** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 253 (actual)

## Conditions studied

- Pre-Exposure Prophylaxis of HIV Infection

## Interventions

- **DRUG:** Lenacapavir Tablet
- **DRUG:** Lenacapavir Injection
- **DRUG:** Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)

## Key facts

- **NCT ID:** NCT06101329
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-17
- **Primary completion:** 2026-07
- **Final completion:** 2028-01
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06101329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06101329, "Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06101329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*